Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera

This article was originally published in The Pink Sheet Daily

Executive Summary

Company is pursuing priority review, eyes FDA-approval in mid-2012. If Quad is cleared, newly-approved Complera will take back seat.

You may also be interested in...



Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo

Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.

It’s Not Just Dosing: Stribild’s Side Effect Profile Could Give It An Edge In HIV Market

Gilead has priced its new 4-in-1 HIV treatment, more commonly referred to as Quad, slightly above the only other integrase inhibitor-based regimen on the market, Merck’s Isentress, but at a 35% premium to its own three-drug combo product, Atripla.

The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild

With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel